Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2002

Study Completion Date

August 31, 2004

Conditions
Leukemia, Myelocytic, Acute, Pediatric
Interventions
DRUG

clofarabine (IV formulation)

Trial Locations (18)

15213

Children's Hospital, Pittsburgh

21231

Johns Hopkins Children's Center, Baltimore

60614

Children's Memorial Hospital, Chicago

67198

University of Nebraska Medical Center, Omaha

72202

Arkansas Children's Hospital, Little Rock

76104

Cook's Children's Medical Center, Fort Worth

90027

Children's Hospital, Los Angeles

Unknown

Children's Hospital, Orange County

Children's Hospital, San Diego

Children's Hospital, Denver

Children's Hospital, St Louis

Memorial Sloan-Kettering, New York

Children's Hospital, Philadelphia

St. Jude Children's Research Hospital, Memphis

Children's Medical Center, Dallas

Texas Children's Cancer Center, Houston

The University of Texas M.D. Anderson Cancer Center, Houston

06106

University of Connecticut Health Center, Hartford

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00042354 - Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients | Biotech Hunter | Biotech Hunter